nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—prostate cancer	0.734	1	CbGaD
Phylloquinone—BGLAP—urine—prostate cancer	0.0218	0.387	CbGeAlD
Phylloquinone—GGCX—Gamma-carboxylation of protein precursors—F9—prostate cancer	0.0122	0.115	CbGpPWpGaD
Phylloquinone—GGCX—Gamma-carboxylation, transport, and amino-terminal cleavage of proteins—F9—prostate cancer	0.0104	0.0976	CbGpPWpGaD
Phylloquinone—GGCX—prostate gland—prostate cancer	0.00763	0.136	CbGeAlD
Phylloquinone—GGCX—seminal vesicle—prostate cancer	0.00645	0.115	CbGeAlD
Phylloquinone—BGLAP—renal system—prostate cancer	0.00533	0.0948	CbGeAlD
Phylloquinone—GGCX—renal system—prostate cancer	0.0052	0.0925	CbGeAlD
Phylloquinone—GGCX—PTM: gamma carboxylation, hypusine formation and arylsulfatase activation—F9—prostate cancer	0.00493	0.0462	CbGpPWpGaD
Phylloquinone—BGLAP—Osteoblast Signaling—TNFSF11—prostate cancer	0.00479	0.0449	CbGpPWpGaD
Phylloquinone—BGLAP—bone marrow—prostate cancer	0.00403	0.0717	CbGeAlD
Phylloquinone—Vitamin E—GSTM3—prostate cancer	0.00401	0.428	CrCbGaD
Phylloquinone—Scleroderma—Docetaxel—prostate cancer	0.00396	0.042	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—ASCL1—prostate cancer	0.00346	0.0324	CbGpPWpGaD
Phylloquinone—GGCX—testis—prostate cancer	0.00336	0.0598	CbGeAlD
Phylloquinone—BGLAP—FGF signaling pathway—IL17RD—prostate cancer	0.00263	0.0247	CbGpPWpGaD
Phylloquinone—GGCX—lymph node—prostate cancer	0.00244	0.0433	CbGeAlD
Phylloquinone—BGLAP—Osteoblast Signaling—PDGFRB—prostate cancer	0.0024	0.0225	CbGpPWpGaD
Phylloquinone—BGLAP—Osteoblast Signaling—ITGB3—prostate cancer	0.00234	0.0219	CbGpPWpGaD
Phylloquinone—Vitamin E—GSTO1—prostate cancer	0.0023	0.246	CrCbGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—GHR—prostate cancer	0.00213	0.0199	CbGpPWpGaD
Phylloquinone—Inflammation—Degarelix—prostate cancer	0.00192	0.0204	CcSEcCtD
Phylloquinone—Injection site reaction—Degarelix—prostate cancer	0.00185	0.0197	CcSEcCtD
Phylloquinone—Swelling—Degarelix—prostate cancer	0.00153	0.0163	CcSEcCtD
Phylloquinone—Injection site reaction—Bicalutamide—prostate cancer	0.0015	0.0159	CcSEcCtD
Phylloquinone—Cyanosis—Conjugated Estrogens—prostate cancer	0.00147	0.0156	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—TUSC3—prostate cancer	0.00145	0.0136	CbGpPWpGaD
Phylloquinone—Atrophy—Prednisone—prostate cancer	0.00142	0.015	CcSEcCtD
Phylloquinone—Vitamin E—GSTA2—prostate cancer	0.00139	0.149	CrCbGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—PLAUR—prostate cancer	0.00135	0.0126	CbGpPWpGaD
Phylloquinone—Necrosis—Conjugated Estrogens—prostate cancer	0.00132	0.0141	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—GJA1—prostate cancer	0.00131	0.0123	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—GALNT3—prostate cancer	0.00129	0.0121	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—PARP1—prostate cancer	0.00128	0.012	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—SPON2—prostate cancer	0.00118	0.0111	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—FGFR4—prostate cancer	0.00115	0.0107	CbGpPWpGaD
Phylloquinone—Sweating—Nilutamide—prostate cancer	0.00112	0.0119	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—NCOA1—prostate cancer	0.00112	0.0105	CbGpPWpGaD
Phylloquinone—Flushing—Estramustine—prostate cancer	0.0011	0.0117	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—AR—prostate cancer	0.00107	0.01	CbGpPWpGaD
Phylloquinone—Inflammation—Conjugated Estrogens—prostate cancer	0.00107	0.0114	CcSEcCtD
Phylloquinone—Injection site reaction—Goserelin—prostate cancer	0.00104	0.0111	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—RPN2—prostate cancer	0.00103	0.00969	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—DNMT1—prostate cancer	0.00103	0.00965	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—PLAUR—prostate cancer	0.000997	0.00934	CbGpPWpGaD
Phylloquinone—Necrosis—Mitoxantrone—prostate cancer	0.000987	0.0105	CcSEcCtD
Phylloquinone—Vitamin E—NQO1—prostate cancer	0.000956	0.102	CrCbGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—PLAU—prostate cancer	0.000946	0.00887	CbGpPWpGaD
Phylloquinone—Cyanosis—Etoposide—prostate cancer	0.00091	0.00967	CcSEcCtD
Phylloquinone—Erythema—Flutamide—prostate cancer	0.000909	0.00965	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—PRKACB—prostate cancer	0.000901	0.00844	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—GCNT1—prostate cancer	0.000897	0.0084	CbGpPWpGaD
Phylloquinone—Immune system disorder—Estradiol valerate/Dienogest—prostate cancer	0.00089	0.00945	CcSEcCtD
Phylloquinone—Phlebitis—Conjugated Estrogens—prostate cancer	0.000875	0.0093	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—PDIA3—prostate cancer	0.000863	0.00809	CbGpPWpGaD
Phylloquinone—Swelling—Goserelin—prostate cancer	0.000863	0.00917	CcSEcCtD
Phylloquinone—Inflammation—Estradiol—prostate cancer	0.000857	0.0091	CcSEcCtD
Phylloquinone—Swelling—Conjugated Estrogens—prostate cancer	0.000855	0.00908	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—NCOA2—prostate cancer	0.00085	0.00796	CbGpPWpGaD
Phylloquinone—Immune system disorder—Degarelix—prostate cancer	0.000846	0.00899	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND2—prostate cancer	0.000839	0.00786	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—B4GALT4—prostate cancer	0.000834	0.00781	CbGpPWpGaD
Phylloquinone—Necrosis—Etoposide—prostate cancer	0.000821	0.00872	CcSEcCtD
Phylloquinone—Flushing—Cabazitaxel—prostate cancer	0.000819	0.0087	CcSEcCtD
Phylloquinone—Erythema—Degarelix—prostate cancer	0.000815	0.00866	CcSEcCtD
Phylloquinone—Sweating—Bicalutamide—prostate cancer	0.000808	0.00859	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—F9—prostate cancer	0.000807	0.00757	CbGpPWpGaD
Phylloquinone—Anaphylactic shock—Estrone—prostate cancer	0.000802	0.00852	CcSEcCtD
Phylloquinone—Immune system disorder—Cabazitaxel—prostate cancer	0.000797	0.00847	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—HIF1A—prostate cancer	0.000789	0.00739	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Conjugated Estrogens—prostate cancer	0.000779	0.00827	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—FGFR2—prostate cancer	0.000769	0.00721	CbGpPWpGaD
Phylloquinone—Erythema—Cabazitaxel—prostate cancer	0.000768	0.00816	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—ICAM1—prostate cancer	0.000763	0.00715	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—MUC4—prostate cancer	0.000763	0.00714	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—KDR—prostate cancer	0.000755	0.00707	CbGpPWpGaD
Phylloquinone—Dyspnoea—Estramustine—prostate cancer	0.000748	0.00795	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—prostate cancer	0.000746	0.00699	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—SIRT1—prostate cancer	0.000744	0.00697	CbGpPWpGaD
Phylloquinone—Dyspnoea—Abiraterone—prostate cancer	0.000727	0.00772	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—EGR1—prostate cancer	0.000727	0.00681	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Nilutamide—prostate cancer	0.00072	0.00765	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—NCOA1—prostate cancer	0.000716	0.00671	CbGpPWpGaD
Phylloquinone—Vitamin E—GSTP1—prostate cancer	0.000707	0.0755	CrCbGaD
Phylloquinone—Phlebitis—Estradiol—prostate cancer	0.0007	0.00744	CcSEcCtD
Phylloquinone—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.0007	0.00744	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PLAU—prostate cancer	0.000699	0.00655	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—prostate cancer	0.000699	0.00655	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—TUSC3—prostate cancer	0.000689	0.00645	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—IGFBP6—prostate cancer	0.000689	0.00645	CbGpPWpGaD
Phylloquinone—Pain—Estrone—prostate cancer	0.000686	0.00729	CcSEcCtD
Phylloquinone—Swelling—Estradiol—prostate cancer	0.000684	0.00727	CcSEcCtD
Phylloquinone—Immune system disorder—Bicalutamide—prostate cancer	0.000684	0.00726	CcSEcCtD
Phylloquinone—Necrosis—Docetaxel—prostate cancer	0.000682	0.00725	CcSEcCtD
Phylloquinone—Anaphylactic shock—Degarelix—prostate cancer	0.000665	0.00707	CcSEcCtD
Phylloquinone—Inflammation—Etoposide—prostate cancer	0.000664	0.00706	CcSEcCtD
Phylloquinone—Dyspnoea—Nilutamide—prostate cancer	0.000664	0.00705	CcSEcCtD
Phylloquinone—Phlebitis—Mitoxantrone—prostate cancer	0.000653	0.00693	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—MAP2K1—prostate cancer	0.000649	0.00608	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CREBBP—prostate cancer	0.000645	0.00604	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Degarelix—prostate cancer	0.000643	0.00683	CcSEcCtD
Phylloquinone—Swelling—Mitoxantrone—prostate cancer	0.000637	0.00677	CcSEcCtD
Phylloquinone—Pain—Nilutamide—prostate cancer	0.000637	0.00677	CcSEcCtD
Phylloquinone—Injection site pain—Capecitabine—prostate cancer	0.000635	0.00674	CcSEcCtD
Phylloquinone—Sweating increased—Conjugated Estrogens—prostate cancer	0.000635	0.00674	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Estradiol—prostate cancer	0.000623	0.00662	CcSEcCtD
Phylloquinone—Hypotension—Degarelix—prostate cancer	0.000622	0.00661	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—prostate cancer	0.00062	0.00581	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—SSR2—prostate cancer	0.000614	0.00575	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—GALNT3—prostate cancer	0.000614	0.00575	CbGpPWpGaD
Phylloquinone—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000599	0.00636	CcSEcCtD
Phylloquinone—Dyspnoea—Degarelix—prostate cancer	0.000593	0.0063	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—JAK2—prostate cancer	0.000591	0.00554	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Docetaxel—prostate cancer	0.000589	0.00625	CcSEcCtD
Phylloquinone—Necrosis—Prednisone—prostate cancer	0.000588	0.00625	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—BCL2—prostate cancer	0.000586	0.00549	CbGpPWpGaD
Phylloquinone—Hypotension—Cabazitaxel—prostate cancer	0.000586	0.00622	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—BAX—prostate cancer	0.000585	0.00548	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Mitoxantrone—prostate cancer	0.000581	0.00617	CcSEcCtD
Phylloquinone—Immune system disorder—Ethinyl Estradiol—prostate cancer	0.000578	0.00614	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—prostate cancer	0.000578	0.00541	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—prostate cancer	0.000573	0.00537	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Capecitabine—prostate cancer	0.00057	0.00606	CcSEcCtD
Phylloquinone—Pain—Degarelix—prostate cancer	0.000569	0.00605	CcSEcCtD
Phylloquinone—Sweating—Goserelin—prostate cancer	0.000562	0.00597	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—HERPUD1—prostate cancer	0.000562	0.00526	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—SPON2—prostate cancer	0.000562	0.00526	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—JAK2—prostate cancer	0.000561	0.00526	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—prostate cancer	0.000561	0.00525	CbGpPWpGaD
Phylloquinone—Dyspnoea—Cabazitaxel—prostate cancer	0.000559	0.00594	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—NR3C1—prostate cancer	0.000555	0.0052	CbGpPWpGaD
Phylloquinone—Inflammation—Docetaxel—prostate cancer	0.000552	0.00586	CcSEcCtD
Phylloquinone—Phlebitis—Etoposide—prostate cancer	0.000543	0.00577	CcSEcCtD
Phylloquinone—Pain—Cabazitaxel—prostate cancer	0.000536	0.00569	CcSEcCtD
Phylloquinone—Inflammation—Capecitabine—prostate cancer	0.000534	0.00568	CcSEcCtD
Phylloquinone—Injection site reaction—Docetaxel—prostate cancer	0.000532	0.00565	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—prostate cancer	0.000532	0.00498	CbGpPWpGaD
Phylloquinone—Dizziness—Estrone—prostate cancer	0.00053	0.00563	CcSEcCtD
Phylloquinone—Swelling—Etoposide—prostate cancer	0.00053	0.00563	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—KLK3—prostate cancer	0.000522	0.00489	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Bicalutamide—prostate cancer	0.00052	0.00552	CcSEcCtD
Phylloquinone—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000516	0.00548	CcSEcCtD
Phylloquinone—Injection site reaction—Capecitabine—prostate cancer	0.000515	0.00547	CcSEcCtD
Phylloquinone—Sweating increased—Estradiol—prostate cancer	0.000508	0.0054	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CDKN1B—prostate cancer	0.0005	0.00468	CbGpPWpGaD
Phylloquinone—Dizziness—Nilutamide—prostate cancer	0.000493	0.00523	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CREBBP—prostate cancer	0.000491	0.0046	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—RPN2—prostate cancer	0.000491	0.0046	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—KLK2—prostate cancer	0.000491	0.0046	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—MBTPS1—prostate cancer	0.000491	0.0046	CbGpPWpGaD
Phylloquinone—Dizziness—Flutamide—prostate cancer	0.00049	0.00521	CcSEcCtD
Phylloquinone—Hypersensitivity—Degarelix—prostate cancer	0.00049	0.00521	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Etoposide—prostate cancer	0.000483	0.00513	CcSEcCtD
Phylloquinone—Dyspnoea—Bicalutamide—prostate cancer	0.000479	0.00509	CcSEcCtD
Phylloquinone—Immune system disorder—Goserelin—prostate cancer	0.000476	0.00505	CcSEcCtD
Phylloquinone—Sweating increased—Mitoxantrone—prostate cancer	0.000473	0.00503	CcSEcCtD
Phylloquinone—Immune system disorder—Conjugated Estrogens—prostate cancer	0.000471	0.005	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—TCP1—prostate cancer	0.000465	0.00436	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—ICAM1—prostate cancer	0.000464	0.00434	CbGpPWpGaD
Phylloquinone—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000463	0.00492	CcSEcCtD
Phylloquinone—Hypersensitivity—Cabazitaxel—prostate cancer	0.000462	0.00491	CcSEcCtD
Phylloquinone—Necrosis—Epirubicin—prostate cancer	0.00046	0.00489	CcSEcCtD
Phylloquinone—Pain—Bicalutamide—prostate cancer	0.00046	0.00489	CcSEcCtD
Phylloquinone—Erythema—Goserelin—prostate cancer	0.000458	0.00487	CcSEcCtD
Phylloquinone—Erythema—Conjugated Estrogens—prostate cancer	0.000454	0.00482	CcSEcCtD
Phylloquinone—Phlebitis—Docetaxel—prostate cancer	0.000451	0.00479	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—SRC—prostate cancer	0.00045	0.00422	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—DNAJC3—prostate cancer	0.000444	0.00416	CbGpPWpGaD
Phylloquinone—Injection site pain—Epirubicin—prostate cancer	0.000442	0.0047	CcSEcCtD
Phylloquinone—Swelling—Docetaxel—prostate cancer	0.000441	0.00468	CcSEcCtD
Phylloquinone—Dizziness—Degarelix—prostate cancer	0.00044	0.00467	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—EP300—prostate cancer	0.000439	0.00411	CbGpPWpGaD
Phylloquinone—Phlebitis—Capecitabine—prostate cancer	0.000437	0.00464	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—STAT3—prostate cancer	0.000434	0.00407	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—GSK3B—prostate cancer	0.000427	0.00401	CbGpPWpGaD
Phylloquinone—Swelling—Capecitabine—prostate cancer	0.000427	0.00453	CcSEcCtD
Phylloquinone—Necrosis—Doxorubicin—prostate cancer	0.000426	0.00452	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—GCNT1—prostate cancer	0.000426	0.00399	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MDM2—prostate cancer	0.000417	0.00391	CbGpPWpGaD
Phylloquinone—Sweating—Mitoxantrone—prostate cancer	0.000415	0.00441	CcSEcCtD
Phylloquinone—Dizziness—Cabazitaxel—prostate cancer	0.000415	0.0044	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—MMP9—prostate cancer	0.000414	0.00388	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CREBBP—prostate cancer	0.000413	0.00387	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—STAT3—prostate cancer	0.000412	0.00386	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—PDIA3—prostate cancer	0.00041	0.00384	CbGpPWpGaD
Phylloquinone—Injection site pain—Doxorubicin—prostate cancer	0.000409	0.00435	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—TGFB1—prostate cancer	0.000402	0.00377	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Epirubicin—prostate cancer	0.000397	0.00422	CcSEcCtD
Phylloquinone—Hypersensitivity—Bicalutamide—prostate cancer	0.000396	0.00421	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—EIF3H—prostate cancer	0.000396	0.00371	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—B4GALT4—prostate cancer	0.000396	0.00371	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—TPP1—prostate cancer	0.000396	0.00371	CbGpPWpGaD
Phylloquinone—Sweating increased—Etoposide—prostate cancer	0.000394	0.00418	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—THBS1—prostate cancer	0.000388	0.00364	CbGpPWpGaD
Phylloquinone—Flushing—Estradiol—prostate cancer	0.000387	0.00412	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—F9—prostate cancer	0.000383	0.00359	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—SRC—prostate cancer	0.000382	0.00358	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1B—prostate cancer	0.000381	0.00357	CbGpPWpGaD
Phylloquinone—Immune system disorder—Estradiol—prostate cancer	0.000377	0.00401	CcSEcCtD
Phylloquinone—Anaphylactic shock—Goserelin—prostate cancer	0.000374	0.00397	CcSEcCtD
Phylloquinone—Inflammation—Epirubicin—prostate cancer	0.000372	0.00395	CcSEcCtD
Phylloquinone—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000371	0.00394	CcSEcCtD
Phylloquinone—GGCX—Post-translational protein modification—CALR—prostate cancer	0.000369	0.00346	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—STAT3—prostate cancer	0.000368	0.00345	CbGpPWpGaD
Phylloquinone—Hyperbilirubinaemia—Doxorubicin—prostate cancer	0.000367	0.0039	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND1—prostate cancer	0.000364	0.00341	CbGpPWpGaD
Phylloquinone—Erythema—Estradiol—prostate cancer	0.000363	0.00386	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MUC4—prostate cancer	0.000362	0.00339	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Goserelin—prostate cancer	0.000362	0.00384	CcSEcCtD
Phylloquinone—Injection site reaction—Epirubicin—prostate cancer	0.000359	0.00381	CcSEcCtD
Phylloquinone—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000358	0.00381	CcSEcCtD
Phylloquinone—Dizziness—Bicalutamide—prostate cancer	0.000356	0.00378	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1A—prostate cancer	0.000352	0.0033	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—MDM2—prostate cancer	0.000351	0.00329	CbGpPWpGaD
Phylloquinone—Hypotension—Goserelin—prostate cancer	0.00035	0.00371	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—prostate cancer	0.000348	0.00326	CbGpPWpGaD
Phylloquinone—Hypotension—Conjugated Estrogens—prostate cancer	0.000346	0.00368	CcSEcCtD
Phylloquinone—Inflammation—Doxorubicin—prostate cancer	0.000344	0.00366	CcSEcCtD
Phylloquinone—Erythema—Mitoxantrone—prostate cancer	0.000339	0.0036	CcSEcCtD
Phylloquinone—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000335	0.00356	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—EP300—prostate cancer	0.000335	0.00314	CbGpPWpGaD
Phylloquinone—Dyspnoea—Goserelin—prostate cancer	0.000334	0.00354	CcSEcCtD
Phylloquinone—Injection site reaction—Doxorubicin—prostate cancer	0.000332	0.00353	CcSEcCtD
Phylloquinone—Dyspnoea—Conjugated Estrogens—prostate cancer	0.00033	0.00351	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CXCL8—prostate cancer	0.000328	0.00307	CbGpPWpGaD
Phylloquinone—Pain—Goserelin—prostate cancer	0.00032	0.0034	CcSEcCtD
Phylloquinone—Pain—Conjugated Estrogens—prostate cancer	0.000317	0.00337	CcSEcCtD
Phylloquinone—Sweating increased—Capecitabine—prostate cancer	0.000317	0.00337	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—RPL12—prostate cancer	0.000316	0.00296	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—PLAUR—prostate cancer	0.000316	0.00296	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL2—prostate cancer	0.000313	0.00294	CbGpPWpGaD
Phylloquinone—Phlebitis—Epirubicin—prostate cancer	0.000304	0.00323	CcSEcCtD
Phylloquinone—Dizziness—Ethinyl Estradiol—prostate cancer	0.000301	0.00319	CcSEcCtD
Phylloquinone—Flushing—Etoposide—prostate cancer	0.0003	0.00319	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—HSP90B1—prostate cancer	0.0003	0.00281	CbGpPWpGaD
Phylloquinone—Anaphylactic shock—Estradiol—prostate cancer	0.000297	0.00315	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CDKN1A—prostate cancer	0.000296	0.00277	CbGpPWpGaD
Phylloquinone—Immune system disorder—Etoposide—prostate cancer	0.000292	0.0031	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—prostate cancer	0.000291	0.00272	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—EIF3A—prostate cancer	0.00029	0.00272	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Estradiol—prostate cancer	0.000287	0.00305	CcSEcCtD
Phylloquinone—Sweating increased—Prednisone—prostate cancer	0.000282	0.003	CcSEcCtD
Phylloquinone—Phlebitis—Doxorubicin—prostate cancer	0.000282	0.00299	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—EP300—prostate cancer	0.000281	0.00264	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—AKT1—prostate cancer	0.00028	0.00262	CbGpPWpGaD
Phylloquinone—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000276	0.00294	CcSEcCtD
Phylloquinone—Hypersensitivity—Goserelin—prostate cancer	0.000276	0.00293	CcSEcCtD
Phylloquinone—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000273	0.0029	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Epirubicin—prostate cancer	0.000271	0.00288	CcSEcCtD
Phylloquinone—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000267	0.00284	CcSEcCtD
Phylloquinone—Dyspnoea—Estradiol—prostate cancer	0.000264	0.00281	CcSEcCtD
Phylloquinone—Hypotension—Mitoxantrone—prostate cancer	0.000258	0.00274	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MME—prostate cancer	0.000258	0.00242	CbGpPWpGaD
Phylloquinone—Pain—Estradiol—prostate cancer	0.000254	0.00269	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000251	0.00266	CcSEcCtD
Phylloquinone—Flushing—Docetaxel—prostate cancer	0.00025	0.00265	CcSEcCtD
Phylloquinone—Dizziness—Goserelin—prostate cancer	0.000247	0.00263	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—GRP—prostate cancer	0.000247	0.00231	CbGpPWpGaD
Phylloquinone—Dyspnoea—Mitoxantrone—prostate cancer	0.000246	0.00262	CcSEcCtD
Phylloquinone—Dizziness—Conjugated Estrogens—prostate cancer	0.000245	0.0026	CcSEcCtD
Phylloquinone—Immune system disorder—Docetaxel—prostate cancer	0.000243	0.00258	CcSEcCtD
Phylloquinone—Flushing—Capecitabine—prostate cancer	0.000242	0.00257	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—RPL10—prostate cancer	0.00024	0.00225	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—AKT1—prostate cancer	0.000237	0.00222	CbGpPWpGaD
Phylloquinone—Pain—Mitoxantrone—prostate cancer	0.000236	0.00251	CcSEcCtD
Phylloquinone—Immune system disorder—Capecitabine—prostate cancer	0.000235	0.0025	CcSEcCtD
Phylloquinone—Erythema—Docetaxel—prostate cancer	0.000234	0.00249	CcSEcCtD
Phylloquinone—Anaphylactic shock—Etoposide—prostate cancer	0.00023	0.00244	CcSEcCtD
Phylloquinone—Erythema—Capecitabine—prostate cancer	0.000227	0.00241	CcSEcCtD
Phylloquinone—Hyperhidrosis—Etoposide—prostate cancer	0.000222	0.00236	CcSEcCtD
Phylloquinone—Hypersensitivity—Estradiol—prostate cancer	0.000218	0.00232	CcSEcCtD
Phylloquinone—Flushing—Prednisone—prostate cancer	0.000215	0.00229	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ATF3—prostate cancer	0.000215	0.00202	CbGpPWpGaD
Phylloquinone—Hypotension—Etoposide—prostate cancer	0.000215	0.00228	CcSEcCtD
Phylloquinone—Immune system disorder—Prednisone—prostate cancer	0.000209	0.00222	CcSEcCtD
Phylloquinone—Dyspnoea—Etoposide—prostate cancer	0.000205	0.00218	CcSEcCtD
Phylloquinone—Hypersensitivity—Mitoxantrone—prostate cancer	0.000204	0.00216	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—IGFBP3—prostate cancer	0.000203	0.0019	CbGpPWpGaD
Phylloquinone—Erythema—Prednisone—prostate cancer	0.000202	0.00214	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—prostate cancer	0.000201	0.00189	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—ACHE—prostate cancer	0.000198	0.00185	CbGpPWpGaD
Phylloquinone—Pain—Etoposide—prostate cancer	0.000197	0.00209	CcSEcCtD
Phylloquinone—Dizziness—Estradiol—prostate cancer	0.000196	0.00208	CcSEcCtD
Phylloquinone—Sweating—Epirubicin—prostate cancer	0.000194	0.00206	CcSEcCtD
Phylloquinone—Anaphylactic shock—Docetaxel—prostate cancer	0.000191	0.00203	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—RPS19—prostate cancer	0.00019	0.00178	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CTSD—prostate cancer	0.000187	0.00175	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—THBS1—prostate cancer	0.000184	0.00173	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL6—prostate cancer	0.000184	0.00173	CbGpPWpGaD
Phylloquinone—Sweating—Doxorubicin—prostate cancer	0.000179	0.0019	CcSEcCtD
Phylloquinone—Hyperhidrosis—Capecitabine—prostate cancer	0.000179	0.0019	CcSEcCtD
Phylloquinone—Hypotension—Docetaxel—prostate cancer	0.000178	0.0019	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CALR—prostate cancer	0.000175	0.00164	CbGpPWpGaD
Phylloquinone—Hypotension—Capecitabine—prostate cancer	0.000173	0.00184	CcSEcCtD
Phylloquinone—Dyspnoea—Docetaxel—prostate cancer	0.00017	0.00181	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—AKT1—prostate cancer	0.00017	0.00159	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Etoposide—prostate cancer	0.000169	0.0018	CcSEcCtD
Phylloquinone—Flushing—Epirubicin—prostate cancer	0.000168	0.00179	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ACE—prostate cancer	0.000167	0.00156	CbGpPWpGaD
Phylloquinone—Dyspnoea—Capecitabine—prostate cancer	0.000165	0.00175	CcSEcCtD
Phylloquinone—Anaphylactic shock—Prednisone—prostate cancer	0.000165	0.00175	CcSEcCtD
Phylloquinone—Immune system disorder—Epirubicin—prostate cancer	0.000164	0.00174	CcSEcCtD
Phylloquinone—Pain—Docetaxel—prostate cancer	0.000163	0.00174	CcSEcCtD
Phylloquinone—Hyperhidrosis—Prednisone—prostate cancer	0.000159	0.00169	CcSEcCtD
Phylloquinone—Pain—Capecitabine—prostate cancer	0.000158	0.00168	CcSEcCtD
Phylloquinone—Erythema—Epirubicin—prostate cancer	0.000158	0.00168	CcSEcCtD
Phylloquinone—Flushing—Doxorubicin—prostate cancer	0.000156	0.00165	CcSEcCtD
Phylloquinone—Dizziness—Etoposide—prostate cancer	0.000152	0.00161	CcSEcCtD
Phylloquinone—Immune system disorder—Doxorubicin—prostate cancer	0.000152	0.00161	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—PLAUR—prostate cancer	0.00015	0.0014	CbGpPWpGaD
Phylloquinone—Erythema—Doxorubicin—prostate cancer	0.000146	0.00155	CcSEcCtD
Phylloquinone—Hypersensitivity—Docetaxel—prostate cancer	0.000141	0.00149	CcSEcCtD
Phylloquinone—Hypersensitivity—Capecitabine—prostate cancer	0.000136	0.00145	CcSEcCtD
Phylloquinone—Anaphylactic shock—Epirubicin—prostate cancer	0.000129	0.00137	CcSEcCtD
Phylloquinone—Dizziness—Docetaxel—prostate cancer	0.000126	0.00134	CcSEcCtD
Phylloquinone—Hyperhidrosis—Epirubicin—prostate cancer	0.000125	0.00132	CcSEcCtD
Phylloquinone—Dizziness—Capecitabine—prostate cancer	0.000122	0.0013	CcSEcCtD
Phylloquinone—Hypersensitivity—Prednisone—prostate cancer	0.000121	0.00129	CcSEcCtD
Phylloquinone—Hypotension—Epirubicin—prostate cancer	0.00012	0.00128	CcSEcCtD
Phylloquinone—Anaphylactic shock—Doxorubicin—prostate cancer	0.000119	0.00127	CcSEcCtD
Phylloquinone—Hyperhidrosis—Doxorubicin—prostate cancer	0.000115	0.00122	CcSEcCtD
Phylloquinone—Dyspnoea—Epirubicin—prostate cancer	0.000115	0.00122	CcSEcCtD
Phylloquinone—Hypotension—Doxorubicin—prostate cancer	0.000111	0.00118	CcSEcCtD
Phylloquinone—Pain—Epirubicin—prostate cancer	0.00011	0.00117	CcSEcCtD
Phylloquinone—Dizziness—Prednisone—prostate cancer	0.000109	0.00116	CcSEcCtD
Phylloquinone—Dyspnoea—Doxorubicin—prostate cancer	0.000106	0.00113	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—LEP—prostate cancer	0.000104	0.000971	CbGpPWpGaD
Phylloquinone—Pain—Doxorubicin—prostate cancer	0.000102	0.00108	CcSEcCtD
Phylloquinone—Hypersensitivity—Epirubicin—prostate cancer	9.49e-05	0.00101	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—INS—prostate cancer	8.85e-05	0.000829	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Doxorubicin—prostate cancer	8.78e-05	0.000933	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—IGF1—prostate cancer	8.56e-05	0.000802	CbGpPWpGaD
Phylloquinone—Dizziness—Epirubicin—prostate cancer	8.52e-05	0.000905	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MMP2—prostate cancer	8.28e-05	0.000776	CbGpPWpGaD
Phylloquinone—Dizziness—Doxorubicin—prostate cancer	7.88e-05	0.000837	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CXCL8—prostate cancer	6.88e-05	0.000645	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—prostate cancer	6.35e-05	0.000595	CbGpPWpGaD
